The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Teva- Pharmaceutical Industries Ltd. ADR shares valued at $952,464 were sold by Kalif Eliyahu Sharon on Jun 12 ’25. At $17.08 per share, Kalif Eliyahu Sharon sold 55,775 shares. The insider’s holdings dropped to 403,288 shares worth approximately $6.79 million following the completion of this transaction.
Also, Kalif Eliyahu Sharon purchased 55,775 shares, netting a total of over 952,466 in proceeds.
Before that, Shields Matthew had sold 6,206 shares from its account. In a trade valued at $105,628, the EVP, Global Operations traded Teva- Pharmaceutical Industries Ltd. ADR shares for $17.02 each. Upon closing the transaction, the insider’s holdings decreased to 6,206 shares, worth approximately $0.17 million.
As published in their initiating research note from Goldman on June 06, 2025, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] has been a Buy and the price target has been revised to $24. Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late May. As of May 12, 2025, JP Morgan has increased its “Neutral” rating to a “an Overweight” for TEVA. Earlier on July 10, 2024, Argus upgraded its rating. Their new recommendation was “a Buy” for TEVA stock which previously was a “a Hold”.
Analyzing TEVA Stock Performance
On last trading session,, Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] rose 1.75% to $16.83. The stock’s lowest price that day was $16.2, but it reached a high of $17.24 in the same session. During the last five days, there has been a surge of approximately 1.51%. Over the course of the year, Teva- Pharmaceutical Industries Ltd. ADR shares have dropped approximately -1.58%.
Support And Resistance Levels for Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
RSI (Relative Strength Index) is 54.63 on the 14-day chart, showing neutral technical sentiment.
Is Teva- Pharmaceutical Industries Ltd. ADR subject to short interest?
Stocks of Teva- Pharmaceutical Industries Ltd. ADR saw a sharp rise in short interest on 2025-07-15 jumping by 13.43 million shares to 53.42 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 40.0 million shares. A jump of 25.13% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.24 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.24.
Which companies own the most shares of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)?
In terms of Teva- Pharmaceutical Industries Ltd. ADR share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 33.01% from the previous closing price of $16.54. Analysts anticipate Teva- Pharmaceutical Industries Ltd. ADR stock to reach 28 by 2025, with the lowest price target being 10. In spite of this, 8 analysts ranked Teva- Pharmaceutical Industries Ltd. ADR stock as Buy at the end of 2025. On March 08, 2024, JP Morgan assigned a price target of “a Neutral” to the stock and upgraded coverage with a $14.
